Catalyst Wire Dossier Catalyst Wire Dossier

GS-5885

GS-5885 · Gilead Sciences
Drug timelines are a Plus or Pro feature.

4 regulatory and trial events tracked for GS-5885, covering 2013-01-21 to 2014-02-11. Get the full timeline:

Most recent: Clinical Trial Update: Oral Antivirals (GS-5885, Tegobuvir, and/or GS-9451) With Peginterferon Alfa 2a and Ribavirin in Treatment Experienced Subjects With Chronic Genotype 1 Hepatitis C Virus Infection [Phase 2]

See pricing